@kujhawk1978 Exactly. And just to add a bit to that, MDT is one of the pillars of the new approach to treating oligometastatic prostate cancer.

In Ye Olden Days (i.e. up to ~5 years ago), most oncologists approached all metastatic prostate cancer the same way: the goal was sequentially-escalating palliative treatment (ADT to ARSI to chemotherapy to the final pain killers) to slow the disease's progression and maintain quality of life until it inevitably killed you in 3–5 years (maybe 7 if you were young and healthy).

Now, things have changed dramatically. Many oncologists distinguish by metastatic load: oligometastatic for just a few metastases (typically under 3–5), polymetastatic for more.

For oligometastatic prostate cancer, they hit it with everything they have up front:

- radiation on each individual metastasis (MDT)

- systemic therapy (ADT+ARSI), and increasingly,

- a large "curative" dose of radiation to the prostate, aka "mothership" as well, to keep from supporting any new or existing metastases.

It's an open debate right now whether oligometastatic prostate cancer can be fully "cured" rather than just managed long term, but studies are showing huge improvements in overall survival and progression-free survival from this new, aggressive approach, applying "curative intent" to treatments for oligometastatic PCa.

(Note: there have also been revolutionary changes in the strategies for treating polymetastatic PCa, but that's not the subject of my post; seach for "triplet therapy".)